Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Dis Esophagus ; 33(10)2020 Oct 12.
Article in English | MEDLINE | ID: mdl-32115648

ABSTRACT

There is debate surrounding the appropriate threshold for lymph node harvest during esophagectomy in patients with esophageal cancer, specifically for those receiving preoperative radiation. The purpose of this study was to determine the impact of lymph node yield on survival in patients receiving preoperative chemoradiation for esophageal cancer. The National Cancer Database (NCDB) was utilized to identify patients with esophageal cancer that received preoperative radiation. The cohort was divided into patients undergoing minimal (<9) or extensive (≥9) lymph node yield. Demographic, operative, and postoperative outcomes were compared between the groups. Kaplan-Meier analysis with the log rank test was used to compare survival between the yield groups. Cox proportional hazards model was used to determine the association between lymph node yield and survival. In total, 886 cases were included: 349 (39%) belonging to the minimal node group and 537 (61%) to the extensive group. Unadjusted 5-year survival was similar between the minimal and extensive groups, respectively (37.3% vs. 38.8%; P > 0.05). After adjustment using Cox regression, extensive lymph node yield was associated with survival (hazard ratio 0.80, confidence interval 0.66-0.98, P = 0.03). This study suggests that extensive lymph node yield is advantageous for patients with esophageal cancer undergoing esophagectomy following induction therapy. This most likely reflects improved diagnosis and staging with extensive yield.


Subject(s)
Esophageal Neoplasms , Lymph Node Excision , Esophageal Neoplasms/pathology , Esophageal Neoplasms/surgery , Esophagectomy , Esophagus/pathology , Humans , Lymph Nodes/pathology , Neoplasm Staging , Proportional Hazards Models , Retrospective Studies , Survival Rate
2.
J Med Primatol ; 47(1): 81-84, 2018 02.
Article in English | MEDLINE | ID: mdl-28671309

ABSTRACT

Recrudescence of latent and dormant viruses may lead to overwhelming viremia in immunosuppressed hosts. In immunocompromised hosts, Simian virus 40 (SV40) reactivation is known to cause nephritis and demyelinating central nervous system disease. Here, we report SV40 viremia leading to fatal interstitial pneumonia in an immunosuppressed host following renal allotransplantation.


Subject(s)
Immunocompromised Host , Kidney Diseases/physiopathology , Macaca mulatta , Monkey Diseases/physiopathology , Pneumonia/physiopathology , Polyomavirus Infections/veterinary , Simian virus 40/physiology , Tumor Virus Infections/veterinary , Animals , Kidney Diseases/virology , Kidney Transplantation/veterinary , Monkey Diseases/virology , Pneumonia/virology , Polyomavirus Infections/complications , Tumor Virus Infections/complications
3.
Am J Transplant ; 17(5): 1193-1203, 2017 May.
Article in English | MEDLINE | ID: mdl-27888551

ABSTRACT

Costimulation blockade (CoB) via belatacept is a lower-morbidity alternative to calcineurin inhibitor (CNI)-based immunosuppression. However, it has higher rates of early acute rejection. These early rejections are mediated in part by memory T cells, which have reduced dependence on the pathway targeted by belatacept and increased adhesion molecule expression. One such molecule is leukocyte function antigen (LFA)-1. LFA-1 exists in two forms: a commonly expressed, low-affinity form and a transient, high-affinity form, expressed only during activation. We have shown that antibodies reactive with LFA-1 regardless of its configuration are effective in eliminating memory T cells but at the cost of impaired protective immunity. Here we test two novel agents, leukotoxin A and AL-579, each of which targets the high-affinity form of LFA-1, to determine whether this more precise targeting prevents belatacept-resistant rejection. Despite evidence of ex vivo and in vivo ligand-specific activity, neither agent when combined with belatacept proved superior to belatacept monotherapy. Leukotoxin A approached a ceiling of toxicity before efficacy, while AL-579 failed to significantly alter the peripheral immune response. These data, and prior studies, suggest that LFA-1 blockade may not be a suitable adjuvant agent for CoB-resistant rejection.


Subject(s)
Abatacept/pharmacology , Graft Rejection/drug therapy , Graft Survival/immunology , Immunologic Memory/immunology , Kidney Transplantation/adverse effects , Lymphocyte Function-Associated Antigen-1/chemistry , T-Lymphocytes/immunology , Animals , Disease Models, Animal , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Rejection/pathology , Graft Survival/drug effects , Immunologic Memory/drug effects , Immunosuppressive Agents/pharmacology , Kidney Function Tests , Lymphocyte Function-Associated Antigen-1/metabolism , Macaca mulatta , Postoperative Complications , T-Lymphocytes/drug effects , T-Lymphocytes/pathology
SELECTION OF CITATIONS
SEARCH DETAIL